Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Liabilities and Shareholders Equity (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Liabilities and Shareholders Equity for 3 consecutive years, with $146.5 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 18.97% to $146.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $778.7 million through Dec 2025, up 17.67% year-over-year, with the annual reading at $146.5 million for FY2025, 18.97% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $146.5 million at Inhibrx Biosciences, down from $177.5 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $307.9 million in Q4 2023, with the low at $146.5 million in Q4 2025.
  • Average Liabilities and Shareholders Equity over 3 years is $218.5 million, with a median of $217.3 million recorded in 2024.
  • The sharpest move saw Liabilities and Shareholders Equity tumbled 41.29% in 2024, then decreased 17.92% in 2025.
  • Over 3 years, Liabilities and Shareholders Equity stood at $307.9 million in 2023, then tumbled by 41.29% to $180.8 million in 2024, then decreased by 18.97% to $146.5 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $146.5 million, $177.5 million, and $212.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.